Výsledky vyhledávání

Akademický článek

CDK4/6 inhibition triggers ICAM1-driven immune response and sensitizes LKB1 mutant lung cancer to immunotherapy

Autor: Xue Bai, Ze-Qin Guo, Yan-Pei Zhang, Zhen-zhen Fan, Li-Juan Liu, Li Liu, Li-Li Long, Si-Cong Ma, Jian Wang, Yuan Fang, Xin-Ran Tang, Yu-Jie Zeng, Xinghua Pan, De-Hua Wu, Zhong-Yi Dong

Publikováno v: Nature Communications, Vol 14, Iss 1, Pp 1-18 (2023)

LKB1 mutations have been associated with primary resistance to immune checkpoint inhibitors in patients with lung cancer. Here the authors show that Lkb1-deficient lung tumors are characterized by defective trafficking and adhesion of T cells and tha

Externí odkaz: https://doaj.org/article/cfa146b2c3c2474eb58cc188c46ec8b0

Zobrazit plný text záznamu

Akademický článek

Interstitial pneumonitis associated with combined regimen of immunotherapy and conventional therapies—pharmacovigilance database analysis with real-world data validation

Autor: Xue-Jun Guo, Xiao-Ting Cai, Zi-Xuan Rong, Yan-Pei Zhang, Yu-Xiang Wen, Xue Bai, Jian Wang, Qiang John Fu, Ze-Qin Guo, Li-Li Long, Si-Cong Ma, Xin-Ran Tang, Li Liu, Jian Guan, Zhong-Yi Dong, De-Hua Wu

Publikováno v: BMC Medicine, Vol 21, Iss 1, Pp 1-12 (2023)

Abstract Background Immune checkpoint inhibitor (ICI) therapy combined with conventional therapies is being broadly applied in non-small cell lung cancer (NSCLC) patients. However, the risk of interstitial pneumonitis (IP) following a combined regime

Externí odkaz: https://doaj.org/article/9b36884ce008485099683e8c140bc2c6

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Organ-specific metastatic landscape dissects PD-(L)1 blockade efficacy in advanced non-small cell lung cancer: applicability from clinical trials to real-world practice

Autor: Si-Cong Ma, Xue Bai, Xue-Jun Guo, Li Liu, Lu-Shan Xiao, Yan Lin, Jia-Le Tan, Xiao-Ting Cai, Yu-Xiang Wen, Hu Ma, Q. John Fu, Meng-Xin Leng, Yan-Pei Zhang, Li-Li Long, Ze-Qin Guo, De-Hua Wu, Jian-Guo Zhou, Zhong-Yi Dong

Publikováno v: BMC Medicine, Vol 20, Iss 1, Pp 1-12 (2022)

Abstract Background Organ-specific metastatic context has not been incorporated into the clinical practice of guiding programmed death-(ligand) 1 [PD-(L)1] blockade, due to a lack of understanding of its predictive versus prognostic value. We aim at

Externí odkaz: https://doaj.org/article/24a3b6c7bf874232b58096c5d956a366

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Experimental Study of the Propagation Process of Dissection Using an Aortic Silicone Phantom

Autor: Qing-Zhuo Chi, Yang-Yang Ge, Zhen Cao, Li-Li Long, Li-Zhong Mu, Ying He, Yong Luan

Publikováno v: Journal of Functional Biomaterials, Vol 13, Iss 4, p 290 (2022)

Background: The mortality of acute aortic dissection (AD) can reach 65~70%. However, it is challenging to follow the progress of AD formation. The purpose of this work was to observe the process of dissection development using a novel tear-embedded s

Externí odkaz: https://doaj.org/article/c22b8710b8684b83b89ac13939f97df8

Zobrazit plný text záznamu

Akademický článek

De Novo Mutation in Non-Tyrosine Kinase Domain of ROS1 as a Potential Predictor of Immune Checkpoint Inhibitors in Melanoma

Autor: Si-Cong Ma, Hong-Bo Zhu, Jian Wang, Yan-Pei Zhang, Xue-Jun Guo, Li-Li Long, Ze-Qin Guo, De-Hua Wu, Zhong-Yi Dong, Xue Bai

Publikováno v: Frontiers in Oncology, Vol 11 (2021)

PurposeDespite the success of targeted therapy in c-ros oncogene 1 (ROS1)-rearranged cancers, especially non-small cell lung cancer (NSCLC), the clinical significance of ROS1 de novo mutation has not yet been understood. We sought to elucidate the pr

Externí odkaz: https://doaj.org/article/de34127cd04f47bc8097330ec0dbe84b

Zobrazit plný text záznamu

Akademický článek

Integrative evaluation of primary and metastatic lesion spectrum to guide anti-PD-L1 therapy of non-small cell lung cancer: results from two randomized studies

Autor: Si-Cong Ma, Xin-Ran Tang, Li-Li Long, Xue Bai, Jian-Guo Zhou, Zhi-Jiao Duan, Jian Wang, Qiang John Fu, Hong-Bo Zhu, Xue-Jun Guo, Yan-Pei Zhang, Ze-Qin Guo, De-Hua Wu, Zhong-Yi Dong

Publikováno v: OncoImmunology, Vol 10, Iss 1 (2021)

Objectives: Clinical benefits of immune-checkpoint blockade (ICB) versus standard chemotherapy have been established in unselected non-small cell lung cancer (NSCLC). However, the response to ICB therapy among patients is heterogeneous in clinical pr

Externí odkaz: https://doaj.org/article/489c09595f1a41e4ad06be021b54b7d7

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání